WO2015022830A1 - エストロジェン分泌増進用組成物、及びその芳香組成物、並びにその芳香用具 - Google Patents

エストロジェン分泌増進用組成物、及びその芳香組成物、並びにその芳香用具 Download PDF

Info

Publication number
WO2015022830A1
WO2015022830A1 PCT/JP2014/068675 JP2014068675W WO2015022830A1 WO 2015022830 A1 WO2015022830 A1 WO 2015022830A1 JP 2014068675 W JP2014068675 W JP 2014068675W WO 2015022830 A1 WO2015022830 A1 WO 2015022830A1
Authority
WO
WIPO (PCT)
Prior art keywords
estrogen
cineole
composition
secretion
estrogen secretion
Prior art date
Application number
PCT/JP2014/068675
Other languages
English (en)
French (fr)
Japanese (ja)
Inventor
一之 篠原
裕和 土居
正太 西谷
Original Assignee
株式会社 マザー＆チャイルド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 株式会社 マザー＆チャイルド filed Critical 株式会社 マザー＆チャイルド
Publication of WO2015022830A1 publication Critical patent/WO2015022830A1/ja

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
    • A61K8/4973—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with oxygen as the only hetero atom
    • A61K8/498—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with oxygen as the only hetero atom having 6-membered rings or their condensed derivatives, e.g. coumarin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/30—Oestrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q13/00—Formulations or additives for perfume preparations

Definitions

  • the present invention relates to an estrogen secretion enhancing composition, an estrogen secretion aroma composition, and an estrogen secretion aroma device containing 1,8-cineole as an active ingredient.
  • Estrogen secretion during pregnancy is tens of times that of women who are not pregnant. Estrogen secretion levels, which have been elevated for almost 9 months, decrease rapidly within hours after delivery and fall to the point where they cannot be measured on day 7. Maternity blue occurs in about 80% of women at this time. Maternity blue, like premenstrual tension, presents unspecified complaints specific to women. Symptoms usually begin 3-5 days after delivery and disappear within 2 weeks. In addition, postpartum depression may occur due to decreased postpartum hormone secretion.
  • Estrogen secretion levels change throughout life. It begins to rise in puberty and reaches its peak in the 20s. Later, ovarian function gradually declined, estrogen decreased, and menopause. Menopause usually occurs between the ages of 45 and 55 and may be early or late. Menopause is seen in 60-70% of women at this time. Symptoms of menopause are mainly women's unspecified complaints similar to premenstrual tension or maternity blue.
  • Patent Document 1 discloses amplet seed oil as a fragrance composition as a secretion promoter for 17 ⁇ -estradiol, which is a main component of estrogen (a group of female hormones). The use of an amblet lid is disclosed.
  • Patent Document 2 discloses the use of an extract of fungal Cordyceps as a treatment for female hormone deficiency.
  • Patent Document 3 is based on the present inventors, and discloses the effect of aroma component of ⁇ -caryophyllene on women.
  • Non-Patent Documents 1 to 3 show that the presentation of odor changes the secretion frequency of luteinizing hormone (LH) controlled by the hypothalamus, and conventional aromatherapy and the like are oral, intravenous, and transdermal.
  • LH luteinizing hormone
  • the possibility of changing hypothalamic function only through the action via the olfactory nerve was shown.
  • estrogen secretion is caused by the secretion of LH
  • LH secretion is caused by the activity of the hypothalamus. Therefore, the effect of increasing the activity of the hypothalamus is considered to cause the increase of estrogen secretion. .
  • estrogen secretion which is 1,8-cineole and the female hormone.
  • Estrogens have been shown to have the following anti-aging effects (or disease risk reduction effects associated with reduced estrogen in menopause and menopausal women).
  • ⁇ Promoting the production of collagen (beautifying skin effect, preventing firmness / shininess)
  • Promoting absorption of calcium into bone reducing risk of osteoporosis
  • Promoting hair renewal (promoting hair growth)
  • Increased basic metabolism prevention of apple-type obesity
  • Cognitive enhancement reducing dementia risk
  • Promoting vasodilation reducing the risk of arteriosclerosis
  • Immune function enhancement reducing risk of autoimmune diseases such as collagen disease and rheumatism
  • Promoting the development of the mammary gland (beauty effect by maintaining the elasticity and elasticity of the breast)
  • Increased good cholesterol (HDL) (reduced risk of arteriosclerosis)
  • the route of action is not limited to the route through the olfactory nerve, but also includes the oral, intravenous, and transdermal routes.
  • the limbic system which is the center of emotion
  • hypothalamus which is the center of instinct (feeding, sleep) hormone
  • An object of the present invention is to provide a composition for enhancing estrogen secretion and the method for enhancing secretion.
  • the present inventors have found that the odor of 1,8-cineole particularly enhances estrogen secretion in late-luteal females.
  • the present invention has been completed based on the above findings, and is an estrogen secretion enhancing composition containing 1,8-cineole as an active ingredient, its fragrance composition, and its fragrance tool.
  • the first aspect of the present invention is the invention according to claim 1, wherein estrogen secretion containing 1,8-cineole synthesized or purified from natural product as an active ingredient is synthesized. It is a composition for enhancing estrogen secretion, characterized by enhancing.
  • the invention of claim 2 is the composition for enhancing estrogen secretion according to claim 1, wherein the estrogen is 17 ⁇ -estradiol.
  • the invention of claim 3 is the composition for enhancing estrogen secretion according to claim 1 or 2, wherein the administration means of the composition is administered so as to be transmitted to the brain via the olfactory nerve by a fragrance, essential oil, or cosmetics. It is characterized by that.
  • the invention of claim 4 is characterized in that, in the composition for enhancing estrogen secretion according to claim 3, the administration means of the composition is administered so as to be transmitted to the brain via the olfactory nerve by food and drink.
  • the invention according to claim 5, which is the second aspect of the present invention comprises synthesized 1,8-cineol or 1,8-cineole isolated and purified from a natural product as an active ingredient to inhibit estrogen secretion.
  • An estrogen-secreting fragrance composition characterized in that it is enhanced.
  • the invention of claim 6 is the estrogen secretion fragrance composition of claim 5, wherein the estrogen is 17 ⁇ -estradiol.
  • the invention according to claim 7, which is the third aspect of the present invention, comprises 1,8-cineole synthesized or 1,8-cineole isolated and purified from a natural product as an active ingredient to inhibit estrogen secretion. It is an estrogen fragrance tool characterized by improving it.
  • the invention of claim 8 is the estrogen-secreting fragrance device according to claim 7, wherein the estrogen is 17 ⁇ -estradiol.
  • Estrogen secretion enhancing composition, estrogen secretion fragrance composition, and estrogen fragrance composition containing 1,8-cineole isolated and purified from the synthesized 1,8-cineol or natural product of the present invention as an active ingredient Can be used to enhance estrogen secretion, and in particular, estrogen secretion can be further enhanced in the late corpus luteum. For this reason, estrogen is effective in alleviating female-specific indefinite complaints (including illness) such as premenstrual tension, menstrual symptoms, maternity blue, postpartum depression, and menopause, which are caused by decreased estrogen secretion in women. Anti-aging effect due to increased secretion can be expected.
  • composition of the present invention can be administered by a method via the olfactory nerve, it can exert its effect in a short time, and since it does not involve blood, it has the advantage of having no side effects on organs such as the liver and kidney. There is also.
  • 1,8-cineole is particularly estrogen in a woman in the late luteal phase (in the late luteal phase, estrogen decreases and premenstrual tension develops). We found an action to enhance secretion.
  • This 1,8-cineole is a naturally occurring organic compound called eucalyptol (also synthesizable), which is a kind of monoterpenoid with a cyclic ether structure, and is 1,8-cineole. It is also called limonene oxide and cajeptol, and has a fragrance and taste that makes it suitable for food additives, fragrances, and cosmetics, and has the following structural formula.
  • 1,8-cineole has the effect of promoting estrogen secretion in late luteinous women, but has come up with the idea that it can be used for the following novel uses.
  • 1,8-cineole can be presumed to be effective in improving discomfort caused by decreased estrogen secretion in women in the late corpus luteum (including menstrual periods) and in women after childbirth . Discomfort caused by decreased estrogen secretion is seen not only in women in the late corpus luteum (including menstrual periods), but also in women after childbirth and women in menopause. It can be assumed that 1,8-cineole is effective. Moreover, it can be estimated that the above-mentioned anti-aging effect is obtained.
  • composition for enhancing estrogen secretion contains 1,8-cineole as an active ingredient.
  • the 1,8-cineole to be used may be extracted from natural products (for example, tea tree, peppermint, eucalyptus, rosemary, etc.) or may be artificially synthesized.
  • 1,8-cineole is already sold as a reagent and may be used.
  • the composition for enhancing estrogen secretion of the present invention is prepared in various compositions depending on the use mode, and is usually prepared in the same composition as the estrogen secreting fragrance composition described later.
  • the estrogen-secreting fragrance composition of the present invention is prepared in various compositions depending on the use mode, but usually the 1,8-cineole concentration is 0.3 to 3.75%, preferably 1.5. %
  • a suitable solvent such as dipropylene glycol, propylene glycol, butylene glycol, mineral oil, triethyl citrate, ethanol, benzyl benzoate.
  • the aroma is inhaled as an aromatic bath using an aroma pot or a diffuser.
  • other components can be added and used as cosmetics (skin care products, perfumes, etc.), bathing agents, fragrances, sprays, massage oils, shampoos, laundry detergents and the like.
  • Estrogen secretion fragrance tool has a portion containing synthesized 1,8-cineole or 1,8-cineole isolated and purified from natural products.
  • the 1,8-cineole to be used is synthesized or isolated from a natural product and purified in the same manner as the fragrance composition.
  • the food is usually smelled before it is put into the mouth or during mastication. Therefore, 1,8-cineole can exert its effect even in the form of food or beverage, and 1,8-cineole can also be used as a food or drink for improving indefinite complaint symptoms of women.
  • the types of food and drink are not limited, and examples include flavor tea, flavor coffee, flavor beer, rice cake, gum, breath care, seasoning and the like.
  • the food of the present invention is produced by adding a process of adding 1,8-cineole to the normal food production process, and the content of 1,8-cineole in the food depends on the type of food. Normally, the appropriate amount is about 0.3-3.75%.
  • the fragrance device may be any device or tool used for fragrance, sanitary products, paper, textile products (underwear, stocking, etc.), patch medicine, soap, candle, pillow, futon, Etc. can be illustrated.
  • the fragrance tool of the present invention can be produced in the same manner as a general fragrance tool, except that 1,8-cineole is used instead of plant essential oil.
  • the use target and the administration method of the composition for enhancing estrogen secretion of the present invention are characterized in that 1,8-cineole is administered to a person who shows a decrease in estrogen. It is.
  • the administration method of 1,8-cineole is not particularly limited, and it may be administered orally, intravenously, or transdermally in the same manner as ordinary pharmaceuticals, etc., but preferably stimulated by 1,8-cineole. It is administered by a means that is transmitted to the brain via the olfactory nerve.
  • a means for allowing a person who shows a decrease in estrogen secretion to air containing 1,8-cineole can be exemplified.
  • the amount of 1,8-cineole in the air at this time cannot be measured strictly, but the content of 1,8-cineole used in the solution that emits a fragrance is, for example, when propylene glycol is used as a solvent. Is preferably in the range of 0.3 to 3.75%, more preferably about 1.5%.
  • Example 1 We examined hormonal changes that occurred when 1,8-cineole was sniffed in non-smoking women in their twenties who were healthy and mentally healthy who returned to the normal menstrual cycle (26th to 34th).
  • the enzyme immunoassay used above was a salivary component quantification kit (measurement kit) manufactured by SALIMETRICS, whose model number was 1-3702 Estradiol, EIA Kit, High Sensitivity, Salivary, and the measurement method was (A ) “A saliva sample containing an unknown concentration of 17 ⁇ -estradiol” is reacted with an antibody that binds to it (coated on a hole in a plastic plate called a 96-well plate). The known concentration of 17 ⁇ estradiol ” was also reacted at the same time, and a competitive reaction was carried out between (A) and (B) (antibodies were exchanged between (A) and (B)).
  • “Horseradish peroxidase” which is an enzyme used in the enzyme immunoassay has the following physical properties. Peroxidase (Hydrogen peroxidase, Horseradish peroxidase, HRP) Reaction Chromogenic substrate + H 2 O 2 Oxidized dye + 2H 2 O Origin Horseradish Molecular weight, 40,000, optimum pH: pH 6.5 Substrate specificity There is no specificity for chromogenic substrates (hydrogen donors).
  • Example 1 A comparative experiment was conducted using 1.5% of 1,8-cineole dissolved in propylene glycol and Comparative Example 1: only propylene glycol (PG) as a control.
  • the test subjects are 11 persons in total of 6 persons in the follicular phase and 5 persons in the late luteal phase (Late Luteal Phase), and the experimental results of Comparative Example 1 and Example 1 are shown.
  • Example 1 The comparison results of Example 1 and Comparative Example 1 before and after the experiment showed that the concentration of 17 ⁇ estradiol (E2) secreted in Example 1 was significantly increased from 3.1 pg / ml to 3.4 pg / ml ( In contrast to the paired t-test, P ⁇ 0.05), Comparative Example 1 showed no difference in concentration from 3.0 pg / ml to 3.0 pg / ml. When these changes (after sniffing-before sniffing) were compared (PG vs 1,8-Cineole), the concentration of 17 ⁇ estradiol (E2) was significantly increased compared to propylene glycol (PG) in the control (corresponding to A t test, P ⁇ 0.05).
  • PG propylene glycol
  • ANT attention network task
  • the subject's task is to answer the direction of the center arrow among the five arrows as quickly and accurately as possible using the numeric keypad buttons (RT: reaction time).
  • the central arrow is called a target stimulus, and the other four arrows are called distractor stimuli.
  • a total of four cue stimulus conditions are presented.
  • the cue stimulus is not displayed.
  • a cue stimulus is presented at the position of the gazing point, that is, at the center of the screen.
  • the cue stimulus is presented at the position where the target stimulus is presented. That is, when the arrow is presented above the gazing point, the cue stimulus is also presented above the gazing point.
  • a cue stimulus is presented at a position symmetrical to the target stimulus with respect to a horizontal line crossing the center of the screen. That is, when the target stimulus is presented above the gazing point, the cue stimulus is presented at a position opposite to the target stimulus across the gazing point.
  • the Unconscious Dot Probe task is a cognitive task by PC operation, and the change in the index that seems to reflect the libido before and after smelling 1,8-cineole (1.5%) and the case of PG (control)
  • the comparison was performed on six subjects in the late luteal phase.
  • the Unconscious Dot Probe task is a verification tool developed to assess human attention bias. In the experiment in this example, a male nude image was used as the visual stimulus used for the task, and how much attention (bias) to the image is considered as an index reflecting sexual desire was measured. However, the stimulus image presentation time was 17 ms (below the perceptible threshold), and the measurement was performed using the Dot Probe task under the threshold (Uncoscious).
  • PANAS The Positive and Negative Affect Schedule
  • PANAS is a test that answers emotional question items from two scales of “positive emotion” and “negative emotion”.
  • the results of these experiments are the graphs of FIG. 5, and before and after sniffing 1,8-cineole of the example of the present invention, positive emotions increased and negative emotions decreased compared to control (PG).
  • STAI Staize and Trait Anxiety Inventry
  • STAI is a test that answers questions about anxiety status and characteristics from two scales of “state anxiety” and “characteristic anxiety”. Explaining these experimental results with the graph of FIG. 14, before and after sniffing 1,8-cineole, state anxiety decreased compared to control (PG). As can be seen from the results of each of these tests, anxiety can be reduced.
  • a composition for enhancing estrogen secretion containing 1,8-cineole synthesized or isolated from natural products and purified as an active ingredient.
  • the estrogen secretion fragrance composition and the estrogen fragrance device can be used on women to enhance estrogen secretion. For this reason, the effects of alleviating women-specific indefinite complaints (including illness) such as premenstrual tension, menstrual symptoms, maternity blue, postpartum depression, and menopause, which are associated with decreased estrogen secretion, increased estrogen secretion, especially The anti-aging effect can be expected due to the enhanced estrogen secretion in the late corpus luteum.
  • composition of the present invention can be administered by a method via the olfactory nerve, it can exert its effect in a short time, and since it does not involve blood, it has the advantage of having no side effects on organs such as the liver and kidney. There is also.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Birds (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Pregnancy & Childbirth (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Cosmetics (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
PCT/JP2014/068675 2013-08-10 2014-07-14 エストロジェン分泌増進用組成物、及びその芳香組成物、並びにその芳香用具 WO2015022830A1 (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2013167197A JP5923468B2 (ja) 2013-08-10 2013-08-10 エストロジェン分泌増進用組成物、及びその芳香組成物、並びにその芳香用具。
JP2013-167197 2013-08-10

Publications (1)

Publication Number Publication Date
WO2015022830A1 true WO2015022830A1 (ja) 2015-02-19

Family

ID=52468220

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2014/068675 WO2015022830A1 (ja) 2013-08-10 2014-07-14 エストロジェン分泌増進用組成物、及びその芳香組成物、並びにその芳香用具

Country Status (2)

Country Link
JP (1) JP5923468B2 (es)
WO (1) WO2015022830A1 (es)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2015036367A (ja) * 2013-08-10 2015-02-23 株式会社マザー＆チャイルド エストロジェン分泌増進用組成物、及びその芳香組成物、並びにその芳香用具。

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2018104378A (ja) * 2016-12-27 2018-07-05 株式会社マザー＆チャイルド 女性月経周期における各月経ステージに対応する集中力向上・衝動性低下の作用を有する芳香用組成物。

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011152007A1 (ja) * 2010-05-31 2011-12-08 株式会社資生堂 交感神経抑制剤及び皮膚温度低下剤並びにそれを含有する化粧料、食品、及び雑貨

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5923468B2 (ja) * 2013-08-10 2016-05-24 株式会社マザー＆チャイルド エストロジェン分泌増進用組成物、及びその芳香組成物、並びにその芳香用具。

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011152007A1 (ja) * 2010-05-31 2011-12-08 株式会社資生堂 交感神経抑制剤及び皮膚温度低下剤並びにそれを含有する化粧料、食品、及び雑貨

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
HOWES MJ ET AL.: "Assessment of estrogenic activity in some common essential oil constituents.", J PHARM PHARMACOL., vol. 54, no. 11, 2002, pages 1521 - 8, XP008070324, DOI: doi:10.1211/002235702216 *
PERRY NS ET AL.: "In-vitro activity of S. lavandulaefolia ( Spanish sage) relevant to treatment of Alzheimer's disease.", J PHARM PHARMACOL, vol. 53, no. 10, 2001, pages 1347 - 56, XP009027602, DOI: doi:10.1211/0022357011777846 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2015036367A (ja) * 2013-08-10 2015-02-23 株式会社マザー＆チャイルド エストロジェン分泌増進用組成物、及びその芳香組成物、並びにその芳香用具。

Also Published As

Publication number Publication date
JP5923468B2 (ja) 2016-05-24
JP2015036367A (ja) 2015-02-23

Similar Documents

Publication Publication Date Title
Clarkson et al. Controversies about HRT—lessons from monkey models
Prager et al. A randomized, double-blind, placebo-controlled trial to determine the effectiveness of botanically derived inhibitors of 5-α-reductase in the treatment of androgenetic alopecia
Coleman et al. Gender dysphoria: Interdisciplinary approaches in clinical management
JP4805589B2 (ja) エストロゲン様作用剤
KR20030067595A (ko) 수면 및 수면-관련 거동에 영향을 주는 방법
Inaba et al. Human body odor: etiology, treatment, and related factors
JP5116942B2 (ja) プロジェステロンの変化に伴う不快症状の改善用組成物、及びその芳香治療用組成物、並びにその芳香治療用具
KR101074955B1 (ko) 생리/심리적 치료 효과를 갖는 향료 조성물
Price Aromatherapy for Common Ailments: How to use essential oils--such as Rosemary, Chamomile, and Lavender--to prevent and treat more than 40 common ailments
JP5923468B2 (ja) エストロジェン分泌増進用組成物、及びその芳香組成物、並びにその芳香用具。
JP2024069378A (ja) 老化によって引き起こされる女性の障害を緩和するためのサプリメント
JP2004522484A (ja) 哺乳類動物における慢性的ストレスを減少するための方法
Dog et al. An integrative approach to menopause
JP5923469B2 (ja) エストロジェン及びテストステロン分泌増進用組成物、及びその芳香用組成物、並びにその芳香用具。
US9730973B2 (en) Method for restoring male sex drive (libido)
JP7162856B2 (ja) 更年期女性用のエストロジェン分泌を増進させる芳香治療用組成物、芳香治療用入浴剤、芳香治療用食品、及び、芳香治療用具
JP2020007261A (ja) 女性用のテストステロン分泌を増進させるテストステロン分泌増進用組成物、芳香治療用組成物、芳香治療用入浴剤、芳香治療用食品、及び、芳香治療用具
US20170333475A1 (en) Food Supplement for Restoring Male Sex Drive (Libido)
WO2021172304A1 (ja) エストロジェン分泌増進用組成物
JP2006282509A (ja) 抑うつ気分の改善用組成物
CA3097836A1 (en) Compositions for treating female sexual dysfunction
JP2019104730A (ja) 認知機能向上用組成物
JPH11343497A (ja) 化粧料
JP2007008862A (ja) Ｄｈｅａ産生促進剤、美容方法およびｄｈｅａ産生促進剤の使用方法
KR20190024623A (ko) 팔마로사 오일을 포함하는 심리적 안정용 에센셜 오일 조성물 및 멀티모달 생체신호 측정기술을 이용한 심리적 안정용 에센셜 오일 조성물의 향취 효능 검증방법

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 14835960

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 14835960

Country of ref document: EP

Kind code of ref document: A1